Oorja Bio launched with $30 million in seed funding to develop a novel approach for idiopathic pulmonary fibrosis, a disease with limited treatment options. The new company’s strategy focuses on reversing lung scarring, drawing on founders and leadership with prior Acceleron experience. The launch follows broader attention to difficult-to-treat fibrotic disease areas, where investors and pharma are increasingly focused on disease-modifying outcomes rather than symptom management. Oorja is positioned to advance its in-licensed, distinct mechanism while building an internal development engine. For the sector, the deal highlights continued appetite for fibrosis risk-taking—especially where investors see room for meaningful efficacy differentiation.